|
1
|
Cancer Facts and Figures 2009. American
Cancer Society; Atlanta: 2009
|
|
2
|
Coit DG, Andtbacka R, Anker CJ, Bichakjian
CK, Carson WE III, Daud A, Dimaio D, Fleming MD, Guild V, Halpern
AC, et al: Melanoma, version 2.2013: featured updates to the NCCN
guidelines. J Natl Compr Canc Netw. 11:395–407. 2013.
|
|
3
|
Kainthla R, Kim KB and Falchook GS:
Dabrafenib for treatment of BRAF-mutant melanoma. Pharmgenomics
Pers Med. 7:21–29. 2013.
|
|
4
|
Jang S and Atkins MB: Which drug, and
when, for patients with BRAF-mutant melanoma? Lancet Oncol.
14:e60–e69. 2013.
|
|
5
|
Jang S and Atkins MB: Treatment of
BRAF-mutant melanoma: The role of vemurafenib and other therapies.
Clin Pharmacol Ther. 95:24–31. 2014.
|
|
6
|
Homet B and Ribas A: New drug targets in
metastatic melanoma. J Pathol. 232:134–141. 2014.
|
|
7
|
Nihal M, Wu J and Wood GS: Methotrexate
inhibits the viability of human melanoma cell lines and enhances
Fas/Fas-ligand expression, apoptosis and response to
interferon-alpha: Rationale for its use in combination therapy.
Arch Biochem Biophys. 563:101–107. 2014.
|
|
8
|
Yoshino A, Tashiro S, Ogino A, Yachi K,
Ohta T, Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Sano E, et
al: Gene expression profiles predicting the response to IFN-β and a
combination of temozolomide and IFN-β in malignant gliomas. Int J
Oncol. 39:529–542. 2011.
|
|
9
|
Li RH, Hou XY, Yang CS, Liu WL, Tang JQ,
Liu YQ and Jiang G: Temozolomide for treating malignant melanoma. J
Coll Physicians Surg Pak. 25:680–688. 2015.
|
|
10
|
Harries M, Malvehy J, Lebbe C, Heron L,
Amelio J, Szabo Z and Schadendorf D: Treatment patterns of advanced
malignant melanoma (stage III-IV) - A review of current standards
in Europe. Eur J Cancer. 60:179–189. 2016.
|
|
11
|
Losa M, Mazza E, Terreni MR, McCormack A,
Gill AJ, Motta M, Cangi MG, Talarico A, Mortini P and Reni M:
Salvage therapy with temozolomide in patients with aggressive or
metastatic pituitary adenomas: Experience in six cases. Eur J
Endocrinol. 163:843–851. 2010.
|
|
12
|
Zuhur SS, Tanik C, Karaman Ö, Velet S, Çil
E, Öztürk FY, Özkayalar H, Müslüman AM and Altuntaş Y: MGMT
immu-noexpression in growth hormone-secreting pituitary adenomas
and its correlation with Ki-67 labeling index and cytokeratin
distribution pattern. Endocrine. 40:222–227. 2011.
|
|
13
|
Bush ZM, Longtine JA, Cunningham T, Schiff
D, Jane JA Jr, Vance ML, Thorner MO, Laws ER Jr and Lopes MB:
Temozolomide treatment for aggressive pituitary tumors: Correlation
of clinical outcome with O(6)-methylguanine meth-yltransferase
(MGMT) promoter methylation and expression. J Clin Endocrinol
Metab. 95:E280–E290. 2010.
|
|
14
|
Raverot G, Sturm N, de Fraipont F, Muller
M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C,
Assaker R, et al: Temozolomide treatment in aggressive pituitary
tumors and pituitary carcinomas: A French multicenter experience. J
Clin Endocrinol Metab. 95:4592–4599. 2010.
|
|
15
|
Roos WP, Jöst E, Belohlavek C, Nagel G,
Fritz G and Kaina B: Intrinsic anticancer drug resistance of
malignant melanoma cells is abrogated by IFN-β and valproic acid.
Cancer Res. 71:4150–4160. 2011.
|
|
16
|
Sano E, Tashiro S, Tadakuma H, Takei T,
Ueda T and Tsumoto K: Type 1 IFN inhibits the growth factor
deprived apoptosis of cultured human aortic endothelial cells and
protects the cells from chemically induced oxidative cytotoxicity.
J Cell Biochem. 113:3823–3834. 2012.
|
|
17
|
Herndon TM, Demko SG, Jiang X, He K,
Gootenberg JE, Cohen MH, Keegan P and Pazdur R: U.S. food and drug
administration of patients with melanoma. Oncologist. 17:1323–1328.
2012.
|
|
18
|
Baron S, Tyring SK, Fleischmann WR Jr,
Coppenhaver DH, Niesel DW, Klimpel GR, Stanton GJ and Hughes TK:
The interferons Mechanisms of action and clinical applications.
JAMA. 266:1375–1383. 1991.
|
|
19
|
Yoshida J, Kajita Y, Wakabayashi T and
Sugita K: Long-term follow-up results of 175 patients with
malignant glioma: Importance of radical tumour resection and
postoperative adjuvant therapy with interferon, ACNU and radiation.
Acta Neurochir (Wien). 127:55–59. 1994.
|
|
20
|
Chawla-Sarkar M, Leaman DW and Borden EC:
Preferential induction of apoptosis by interferon (IFN)-beta
compared with IFN-alpha2: Correlation with TRAIL/Apo2L induction in
melanoma cell lines. Clin Cancer Res. 7:1821–1831. 2001.
|
|
21
|
García M, del Muro XG, Tres A, Crespo C,
Valladares M, López JJ, Rifà J, Pérez X, Filipovich E and
Germà-Lluch JR: Phase II multicentre study of temozolomide in
combination with interferon alpha-2b in metastatic malignant
melanoma. Melanoma Res. 16:365–370. 2006.
|
|
22
|
Hwu WJ, Panageas KS, Menell JH, Lamb LA,
Aird S, Krown SE, Williams LJ, Chapman PB, Livingston PO, Wolchok
JD, et al: Phase II study of temozolomide plus pegylated
interferon-alpha-2b for metastatic melanoma. Cancer. 106:2445–2451.
2006.
|
|
23
|
Quirt I, Verma S, Petrella T, Bak K and
Charette M: Temozolomide for the treatment of metastatic melanoma:
A systematic review. Oncologist. 12:1114–1123. 2007.
|
|
24
|
Guillot B, Khamari A, Cupissol D, Delaunay
M, Bedane C, Dreno B, Picot MC and Dereure O: Temozolomide
associated with PEG-interferon in patients with metastatic
melanoma: A multicenter prospective phase I/II study. Melanoma Res.
18:141–146. 2008.
|
|
25
|
Spieth K, Kaufmann R, Dummer R, Garbe C,
Becker JC, Hauschild A, Tilgen W, Ugurel S, Beyeler M, Bröcker EB,
et al: Temozolomide plus pegylated interferon alfa-2b as first-line
treatment for stage IV melanoma: A multicenter phase II trial of
the Dermatologic Cooperative Oncology Group (DeCOG). Ann Oncol.
19:801–806. 2008.
|
|
26
|
Ridolfi R, Romanini A, Sileni VC, Michiara
M, Guida M, Biasco G, Poletti P, Amaducci L, Leoni M and Ravaioli
A: Temozolomide and interferon-alpha in metastatic melanoma: A
phase II study of the Italian Melanoma Intergroup. Melanoma Res.
14:295–299. 2004.
|
|
27
|
Yoshino A, Ogino A, Yachi K, Ohta T,
Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N and Sano
E: Effect of IFN-beta on human glioma cell lines with temozolomide
resistance. Int J Oncol. 35:139–148. 2009.
|
|
28
|
Tanaka S, Oka H, Fujii K, Watanabe K,
Nagao K and Kakimoto A: Quantitation of
O6-methylguanine-DNA methyltransferase gene messenger
RNA in gliomas by means of real-time RT-PCR and clinical response
to nitrosoureas. Cell Mol Neurobiol. 25:1067–1071. 2005.
|
|
29
|
Tanaka S, Kobayashi I, Utsuki S, Oka H,
Fujii K, Watanabe T, Nagashima T and Hori T:
O6-methylguanine-DNA methyl-transpherase gene expression
in gliomas by means of real-time quantitative RT-PCR and clinical
response to nitrosoureas. Int J Cancer. 103:67–72. 2003.
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
31
|
Ostermann S, Csajka C, Buclin T, Leyvraz
S, Lejeune F, Decosterd LA and Stupp R: Plasma and cerebrospinal
fluid population pharmacokinetics of temozolomide in malignant
glioma patients. Clin Cancer Res. 10:3728–3736. 2004.
|
|
32
|
Higuchi Y and Hashida M: Pharmacokinetics
of interferon. Clin All-Round. 52:2499–2505. 2003.In Japanese.
|
|
33
|
Naumann SC, Roos WP, Jöst E, Belohlavek C,
Lennerz V, Schmidt CW, Christmann M and Kaina B: Temozolomide- and
fotemustine-induced apoptosis in human malignant melanoma cells:
Response related to MGMT, MMR, DSBs, and p53. Br J Cancer.
100:322–333. 2009.
|
|
34
|
Friedman HS, Keir S, Pegg AE, Houghton PJ,
Colvin OM, Moschel RC, Bigner DD and Dolan ME:
O6-benzylguanine-mediated enhancement of chemotherapy.
Mol Cancer Ther. 1:943–948. 2002.
|
|
35
|
Kaina B, Fritz G, Mitra S and Coquerelle
T: Transfection and expression of human
O6-methylguanine-DNA methyltransferase (MGMT) cDNA in
Chinese hamster cells: The role of MGMT in protection against the
genotoxic effects of alkylating agents. Carcinogenesis.
12:1857–1867. 1991.
|
|
36
|
Chen JM, Zhang YP, Wang C, Sun Y, Fujimoto
J and Ikenaga M: O6-methylguanine-DNA methyltransferase
activity in human tumors. Carcinogenesis. 13:1503–1507. 1992.
|
|
37
|
Kaina B, Ziouta A, Ochs K and Coquerelle
T: Chromosomal instability, reproductive cell death and apoptosis
induced by O6-methylguanine in Mex−,
Mex+ and methylation-tolerant mismatch repair
compromised cells: Facts and models. Mutat Res. 381:227–241.
1997.
|
|
38
|
Liu L, Markowitz S and Gerson SL: Mismatch
repair mutations override alkyltransferase in conferring resistance
to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
Cancer Res. 56:5375–5379. 1996.
|
|
39
|
Hirose Y, Berger MS and Pieper RO: p53
effects both the duration of G2/M arrest and the fate of
temozolomide-treated human glioblastoma cells. Cancer Res.
61:1957–1963. 2001.
|
|
40
|
Beaumont KA, Hill DS, Daignault SM, Lui
GYL, Sharp DM, Gabrielli B, Weninger W and Haass NK: Cell cycle
phase-specific drug resistance as an escape mechanism of melanoma
cells. J Invest Dermatol. 136:1479–1489. 2016.
|
|
41
|
Natsume A, Ishii D, Wakabayashi T, Tsuno
T, Hatano H, Mizuno M and Yoshida J: IFN-beta down-regulates the
expression of DNA repair gene MGMT and sensitizes resistant glioma
cells to temozolomide. Cancer Res. 65:7573–7579. 2005.
|
|
42
|
Levine AJ: p53, the cellular gatekeeper
for growth and division. Cell. 88:323–331. 1997.
|
|
43
|
Takaoka A, Hayakawa S, Yanai H, Stoiber D,
Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, et al:
Integration of interferon-alpha/beta signalling to p53 responses in
tumour suppression and antiviral defence. Nature. 424:516–523.
2003.
|
|
44
|
Zhang X, Fang P, Zhao Z, Ding X, Xie F,
Wang Y and Li C: Antitumorigenic effect of damnacanthal on melanoma
cell viability through p53 and NF-κB/caspase-3 signaling pathways.
Oncol Lett. 16:6039–6044. 2018.
|
|
45
|
el-Deiry WS, Harper JW, O’Connor PM,
Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill
DE, Wang Y, et al: WAF1/CIP1 is induced in p53-mediated
G1 arrest and apoptosis. Cancer Res. 54:1169–1174.
1994.
|
|
46
|
Giandomenico V, Vaccari G, Fiorucci G,
Percario Z, Vannuchi S, Matarrese P, Malorni W, Romeo G and
Affabris GR: Apoptosis and growth inhibition of squamous carcinoma
cells treated with interferon-alpha, IFN-beta and retinoic acid are
associated with induction of the cyclin-dependent kinase inhibitor
p21. Eur Cytokine Netw. 9:619–631. 1998.
|
|
47
|
Miyashita T and Reed JC: Tumor suppressor
p53 is a direct transcriptional activator of the human bax gene.
Cell. 80:293–299. 1995.
|
|
48
|
Wittnebel S, Jalil A, Thiery J, DaRocha S,
Viey E, Escudier B, Chouaib S and Caignard A: The sensitivity of
renal cell carcinoma cells to interferon alpha correlates with
p53-induction and involves Bax. Eur Cytokine Netw. 16:123–127.
2005.
|
|
49
|
Florean C, Song S, Dicato M and Diederich
M: Redox biology of regulated cell death in cancer: A focus on
necroptosis and ferroptosis. Free Radic Biol Med. 134:177–189.
2019.
|
|
50
|
Peter ME, Kischkel FC, Hellbardt S,
Chinnaiyan AM, Krammer PH and Dixit VM: CD95
(APO-1/Fas)-associating signalling proteins. Cell Death Differ.
3:161–170. 1996.
|
|
51
|
Nagata S: Apoptosis by death factor. Cell.
88:355–365. 1997.
|
|
52
|
Tominaga Y, Tsuzuki T, Shiraishi A, Kawate
H and Sekiguchi M: Alkylation-induced apoptosis of embryonic stem
cells in which the gene for DNA-repair, methyltransferase, had been
disrupted by gene targeting. Carcinogenesis. 18:889–896. 1997.
|
|
53
|
Meikrantz W, Bergom MA, Memisoglu A and
Samson L: O6-alkylguanine DNA lesions trigger apoptosis.
Carcinogenesis. 19:369–372. 1998.
|
|
54
|
Kanzawa T, Germano IM, Komata T, Ito H,
Kondo Y and Kondo S: Role of autophagy in temozolomide-induced
cytotoxicity for malignant glioma cells. Cell Death Differ.
11:448–457. 2004.
|
|
55
|
Ling YH, Aracil M, Zou Y, Yuan Z, Lu B,
Jimeno J, Cuervo AM and Perez-Soler R: PM02734 (elisidepsin)
induces caspase-independent cell death associated with features of
autophagy, inhibition of the Akt/mTOR signaling pathway, and
activation of death-associated protein kinase. Clin Cancer Res.
17:5353–5366. 2011.
|
|
56
|
Chen WL, Pan L, Kinghorn AD, Swanson SM
and Burdette JE: Silvestrol induces early autophagy and apoptosis
in human melanoma cells. BMC Cancer. 167:172016.
|
|
57
|
Koga S, Hirohata S, Kondo Y, Komata T,
Takakura M, Inoue M, Kyo S and Kondo S: A novel telomerase-specific
gene therapy: Gene transfer of caspase-8 utilizing the human
telomerase catalytic subunit gene promoter. Hum Gene Ther.
11:1397–1406. 2000.
|
|
58
|
Hou W, Han J, Lu C, Goldstein LA and
Rabinowich H: Autophagic degradation of active caspase-8: A
crosstalk mechanism between autophagy and apoptosis. Autophagy.
6:891–900. 2010.
|
|
59
|
Sistigu A, Yamazaki T, Vacchelli E, Chaba
K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, et
al: Cancer cell-autonomous contribution of type I interferon
signaling to the efficacy of chemotherapy. Nat Med. 20:1301–1309.
2014.
|
|
60
|
Johns TG, Mackay IR, Callister KA, Hertzog
PJ, Devenish RJ and Linnane AW: Antiproliferative potencies of
interferons on melanoma cell lines and xenografts: Higher efficacy
of interferon beta. J Natl Cancer Inst. 84:1185–1190. 1992.
|
|
61
|
Horikoshi T, Fukuzawa K, Hanada N, Ezoe K,
Eguchi H, Hamaoka S, Tsujiya H and Tsukamoto T: In vitro
comparative study of the antitumor effects of human
interferon-alpha, beta and gamma on the growth and invasive
potential of human melanoma cells. J Dermatol. 22:631–636.
1995.
|
|
62
|
Köpf J, Hanson C, Delle U, Weimarck A and
Stierner U: Action of interferon alpha and beta on four human
melanoma cell lines in vitro. Anticancer Res. 16:791–798. 1996.
|
